ABSTRACT
BACKGROUND: Preoperative antibiotic options for pancreaticoduodenectomy (PD) include cefoxitin (CX), piperacillin-tazobactam (PT), or combined cefazolin and metronidazole (CM). Recent studies suggest the superiority of PT over CX, but evidence for CM is unclear. OBJECTIVE: To explore the impact of preoperative antibiotic selection (CM vs. PT and CX vs. PT) on the development of surgical site infections (SSI). METHODS: Consecutive adult patients at one institution who underwent PD from November 2017 to December 2021 and received either CM, PT, or CX preoperatively, were included. The primary outcome was SSI. Secondary outcomes included postoperative infections and clinically significant postoperative pancreatic fistula (POPF). Logistic regression models were used. RESULTS: Among 127 patients included in the study, PT, CM, and CX were administered in 46 (36.2%), 44 (34.6%), and 37 (29.4%) patients, respectively. There were 32 (27.1%) SSI, 20 (36.1%) infections, and 21 (22.9%) POPF events. PT use was associated with reduced risk of SSI compared to CX (OR: 0.32, 95% CI: 0.11-0.89, p = 0.03), but there was no difference as compared to CM (OR: 0.75, 95% CI: 0.27-2.13, p = 0.59). There were no differences in secondary outcomes. CONCLUSION: PT reduced SSI rates compared to CX but was no different to CM among patients undergoing PD at our center.
Subject(s)
Anti-Bacterial Agents , Antibiotic Prophylaxis , Cefazolin , Metronidazole , Pancreaticoduodenectomy , Piperacillin, Tazobactam Drug Combination , Surgical Wound Infection , Humans , Pancreaticoduodenectomy/adverse effects , Male , Female , Retrospective Studies , Surgical Wound Infection/prevention & control , Surgical Wound Infection/epidemiology , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Antibiotic Prophylaxis/methods , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Piperacillin, Tazobactam Drug Combination/therapeutic use , Piperacillin, Tazobactam Drug Combination/administration & dosage , Aged , Middle Aged , Cefazolin/therapeutic use , Cefazolin/administration & dosage , Cefoxitin/administration & dosage , Cefoxitin/therapeutic use , Pancreatic Neoplasms/surgery , Follow-Up Studies , PrognosisABSTRACT
INTRODUCTION: Retention in HIV care is necessary to achieve adherence to antiretroviral therapy, viral load suppression, and optimal health outcomes. There is no standard definition for retention in HIV care, which compromises consistent and reliable reporting and comparison of retention across facilities, jurisdictions, and studies. OBJECTIVE: The objective of this study is to explore how stakeholders involved in HIV care define retention in HIV care and their preferences on measuring retention. METHODS: We will use an exploratory sequential mixed methods design involving HIV stakeholder groups such as people living with HIV, people involved in providing care for PLHIV, and people involved in decision-making about PLHIV. In the qualitative phase of the study, we will conduct 20-25 in-depth interviews to collect the perspectives of HIV stakeholders on using their preferred retention measures. The findings from the qualitative phase will inform the development of survey items for the quantitative phase. Survey participants (n = 385) will be invited to rate the importance of each approach to measuring retention on a seven-point Likert scale. We will merge the qualitative and quantitative findings phase findings to inform a consensus-building framework for a standard definition of retention in care. ETHICAL ISSUES AND DISSEMINATION: This study has received ethics approval from the Hamilton Integrated Research Ethics Board. The findings will be disseminated through peer-reviewed publications, conference presentations, and among stakeholder groups. LIMITATIONS: This study has limitations; we won't be able to arrive at a standard definition; a Delphi technique amongst the stakeholders will be utilized using the framework to reach a consensus globally accepted definition.
Subject(s)
HIV Infections , Research Design , Humans , Surveys and Questionnaires , Consensus , HIV Infections/drug therapy , Viral LoadABSTRACT
BACKGROUND: Cerebrospinal fluid (CSF) galactomannan is an adjunctive test for central nervous system (CNS) aspergillosis diagnosis with unclear diagnostic test characteristics. OBJECTIVES: To evaluate the diagnostic test characteristics of CSF galactomannan in CNS aspergillosis. METHODS: Systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, Web of Science, and Scopus, from inception to 24 February 2023. STUDY ELIGIBILITY CRITERIA: Prospective and retrospective studies with 1-group and 2-group designs using any galactomannan assay on CSF to diagnose CNS aspergillosis. PARTICIPANTS: Adult and/or paediatric patients with CNS aspergillosis. TEST(S): Galactomannan testing on CSF specimens. REFERENCE STANDARD: European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) diagnostic criteria, or equivalent. ASSESSMENT OF RISK OF BIAS: QUADAS-2 assessment in duplicate. METHODS OF DATA SYNTHESIS: Bivariate restricted maximum likelihood estimation random-effects meta-analysis, summarized using forest and summary receiver operating characteristic plots; bivariate meta-regression models to investigate heterogeneity; and subgroup and sensitivity analyses to explore subgroup effects and methodologic choices (PROSPERO registration: CRD42022296331; funding: none). RESULTS: We included eight studies (n = 342 participants). The summary estimates of CSF galactomannan sensitivity and specificity were 69.0% (95% CI, 57.2-78.7%) and 94.4% (95% CI, 82.8-98.3%), respectively. Using meta-regression, galactomannan cut-off (p = 0.38), EORTC/MSGERC criteria version (p = 0.48), or whether the reference standard was defined as both proven and probable or only proven aspergillosis (p = 0.48) did not explain observed heterogeneity. No subgroup effects were demonstrated by analysing the EORTC/MSGERC criteria reference standard used (e.g. 2002 vs. 2008 definitions) or whether paediatric patients were included. Diagnostic sensitivity was improved using a galactomannan cut-off of 1.0, and by excluding high risk of bias and 1-group design studies. DISCUSSION: CSF galactomannan is a highly specific but insensitive test for use as a component of CNS aspergillosis diagnosis. Few included studies, no prospective studies, and a high risk of bias are study limitations.
ABSTRACT
Background: Extracorporeal membrane oxygenation (ECMO) for COVID-19 across Canada has not been well-described. We studied trends for patients with COVID-19-related acute respiratory distress syndrome who received ECMO. Methods: Multicentre retrospective cohort study using data from the Canadian Nosocomial Infection Surveillance Program across four different waves. Surveillance data was collected between March 2020 and June 2022. We reported data stratified by ECMO status and wave. Results: ECMO recipients comprised 299 (6.8%) of the 4,408 critically ill patients included. ECMO recipients were younger (median age 49 versus 62 years, p < 0.001), less likely to be vaccinated against COVID-19 (Wave 4 data: 5.3% versus 19%; p = 0.002), and had fewer comorbidities compared to patients who did not receive ECMO. Thirty-day all-cause mortality was similar between the ECMO and non-ECMO groups (23% versus 26%; p = 0.25). Among ECMO recipients, mortality tended to decrease across Waves 1 to 4: 48%, 31%, 18%, and 16%, respectively (p = 0.04 for trend). However, this was no longer statistically significant when removing the high mortality during Wave 1 (p = 0.15). Conclusions: Our findings suggest that critically ill patients in Canadian hospitals who received ECMO had different characteristics from those who did not receive ECMO. We also observed a trend of decreased mortality over the waves for the ECMO group. Possible explanatory factors may include potential delay in ECMO initiation during Wave 1, evolution of the virus, better understanding of COVID-19 disease and ECMO use, and new medical treatments and vaccines available in later waves. These findings may provide insight for future potential pandemics.
Historique: L'oxygénation extracorporelle en cas de COVID-19 n'est pas bien décrite au Canada. Les chercheurs ont étudié les tendances des patients ayant un syndrome respiratoire aigu lié à la COVID-19 qui ont reçu une oxygénation extracorporelle. Méthodologie: Étude de cohorte rétrospective multicentrique à l'aide de données du Programme canadien de surveillance des infections nosocomiales lors de quatre différentes vagues. Les chercheurs ont recueilli les données de surveillance de mars 2020 à juin 2022. Ils ont rendu compte des données stratifiées en fonction de l'état d'oxygénation extracorporelle et de la vague. Résultats: Les receveurs d'une oxygénation extracorporelle représentaient 299 (6,8 %) des 4 408 patients participants gravement malades. Ils étaient plus jeunes (âge médian de 49 ans par rapport à 62 ans, p<0,001), moins susceptibles d'être vaccinés contre la COVID-19 (données de la quatrième vague 4 : 5,3 % par rapport à 19 %; p=0,002) et présentaient moins d'autres maladies que les patients qui avaient reçu une oxygénation extracorporelle. La mortalité toutes causes confondues au bout de 30 jours était semblable entre le groupe sous oxygénation extracorporelle et celui sans oxygénation extracorporelle (23 % par rapport à 26 %; p=0,25). Chez les receveurs d'une oxygénation extracorporelle, la mortalité avait tendance à diminuer d'une vague à l'autre, soit de 48 %, 31 %, 18 % et 16 % entre la première et la quatrième vague, respectivement (p=0,04 par tendance). Cependant, ces résultats n'étaient plus statistiquement significatifs lorsqu'on excluait le taux de mortalité élevé observé pendant la première vague (p=0,15). Conclusions: Selon les observations des chercheurs, les patients gravement malades des hôpitaux canadiens qui avaient reçu une oxygénation extracorporelle présentaient des caractéristiques différentes de ceux qui n'en avaient pas reçu. Dans le groupe sous oxygénation extracorporelle, ils ont également observé une tendance vers une diminution de la mortalité entre les vagues. Les facteurs explicatifs possibles peuvent inclure un retard potentiel de l'initiation de l'oxygénation extracorporelle pendant la première vague, l'évolution du virus, une meilleure compréhension de la COVID-19, le recours à l'oxygénation extracorporelle, les nouveaux traitements médicaux et les vaccins offerts lors de vagues plus tardives. Ces observations pourraient donner des indications intéressantes lors de futures pandémies. Summary: COVID-19 has affected millions of people. Some patients with COVID-19 develop extremely severe disease requiring advanced critical care. Extracorporeal Membrane Oxygenation (ECMO) is an advanced potentially life-saving technique that can support patients whose lungs are unable to function properly despite using a ventilator (breathing machine). ECMO temporarily takes over lung function, essentially acting as external lungs. ECMO can allow time for the body to heal and potentially improve survival for patients with severe lung failure. The decision to use ECMO is complex and always made by a team of medical professionals who factor in the patient's overall health, medical conditions, and disease severity.We studied the trends for critically ill patients with COVID-19 who received ECMO across Canadian hospitals. We used data collected by trained health care professionals through a Canada-wide program that monitors infections in Canadian hospitals. We compared data between critically ill patients who received and did not receive ECMO, and by wave of the COVID-19 pandemic.Our data found that critically ill patients who received ECMO tended to be younger, have fewer medical conditions, and be less likely to be vaccinated against COVID-19. For patients who received ECMO, the mortality was highest in Wave 1 (48%), then Wave 2 (31%), and similar during Waves 3 and 4 (18% and 16%, respectively). Possible explanations for this trend include potential ECMO delay in Wave 1, the evolution of the virus, a better understanding of ECMO use for COVID-19 and available treatments and vaccines during later waves.In conclusion, our study highlights that critically ill patients who received ECMO in Canada had different features and traits compared to those who did not receive ECMO. As well, our study reported mortality across the waves, with possible explanations for the findings offered. These trends may be helpful in providing insight for future potential pandemics.
ABSTRACT
INTRODUCTION: Informed consent forms (ICFs) for randomised clinical trials (RCTs) can be onerous and lengthy. The process has the potential to overwhelm patients with information, leading them to miss elements of the study that are critical for an informed decision. Specifically, overly long and complicated ICFs have the potential to increase barriers to trial participation for patients with mild cognitive impairment, those who do not speak English as a first language or among those with lower medical literacy. In turn, this can influence trial recruitment, completion and external validity. METHODS AND ANALYSIS: SIMPLY-SNAP is a pragmatic, multicentre, open-label, two-arm parallel-group superiority RCT, nested within a larger trial, the Staphylococcus aureus Network Adaptive Platform (SNAP) trial. We will randomise potentially eligible participants of the SNAP trial 1:1 to a full-length ICF or a SIMPlified LaYered (SIMPLY) consent process where basic information is summarised with embedded hyperlinks to supplemental information and videos. The primary outcome is recruitment into the SNAP trial. Secondary outcomes include patient understanding of the clinical trial, patient and research staff satisfaction with the consent process, and time taken for consent. As an exploratory outcome, we will also compare measures of diversity (eg, gender, ethnicity), according to the consent process randomised to. The planned sample size will be 346 participants. ETHICS AND DISSEMINATION: The study has been approved by the ethics review board (Sunnybrook Health Sciences Research Ethics Board) at sites in Ontario. We will disseminate study results via the SNAP trial group and other collaborating clinical trial networks. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT06168474; www. CLINICALTRIALS: gov).
Subject(s)
COVID-19 , Staphylococcal Infections , Humans , SARS-CoV-2 , Informed Consent , Ontario , Treatment Outcome , Randomized Controlled Trials as Topic , Multicenter Studies as TopicABSTRACT
The WHO Model List of Essential Medicines (EML) prioritizes medicines that have significant global public health value. The EML can also deliver important messages on appropriate medicine use. Since 2017, in response to the growing challenge of antimicrobial resistance, antibiotics on the EML have been reviewed and categorized into three groups: Access, Watch, and Reserve, leading to a new categorization called AWaRe. These categories were developed taking into account the impact of different antibiotics and classes on antimicrobial resistance and the implications for their appropriate use. The 2023 AWaRe classification provides empirical guidance on 41 essential antibiotics for over 30 clinical infections targeting both the primary health care and hospital facility setting. A further 257 antibiotics not included on the EML have been allocated an AWaRe group for stewardship and monitoring purposes. This article describes the development of AWaRe, focussing on the clinical evidence base that guided the selection of Access, Watch, or Reserve antibiotics as first and second choices for each infection. The overarching objective was to offer a tool for optimizing the quality of global antibiotic prescribing and reduce inappropriate use by encouraging the use of Access antibiotics (or no antibiotics) where appropriate. This clinical evidence evaluation and subsequent EML recommendations are the basis for the AWaRe antibiotic book and related smartphone applications. By providing guidance on antibiotic prioritization, AWaRe aims to facilitate the revision of national lists of essential medicines, update national prescribing guidelines, and supervise antibiotic use. Adherence to AWaRe would extend the effectiveness of current antibiotics while helping countries expand access to these life-saving medicines for the benefit of current and future patients, health professionals, and the environment.
Subject(s)
Anti-Bacterial Agents , Antimicrobial Stewardship , Drugs, Essential , World Health Organization , Humans , Anti-Bacterial Agents/therapeutic use , Drugs, Essential/therapeutic use , Bacterial Infections/drug therapy , Practice Guidelines as TopicABSTRACT
Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic. Methods: The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires. Results: From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19. Conclusion: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.